The guinea pig pancreas secretes a single trypsinogen isoform, which is defective in autoactivation

par Ózsvári, Béla, Hegyi, Péter, Sahin-Tóth, Miklós
Publié 2008

Repurposing of FDA-approved drugs against cancer – focus on metastasis

par Ozsvári, Béla, Lamb, Rebecca, Lisanti, Michael P.
Publié dans Aging (Albany NY) (2016)

A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis

par Ozsvari, Bela, Sotgia, Federica, Lisanti, Michael P.
Publié dans Aging (Albany NY) (2017)

Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)

par Ozsvari, Bela, Sotgia, Federica, Lisanti, Michael P.
Publié dans Aging (Albany NY) (2018)

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

par Ózsvári, Béla, Sotgia, Federica, Lisanti, Michael P.
Publié dans Aging (Albany NY) (2020)

Azithromycin and Roxithromycin define a new family of “senolytic” drugs that target senescent human fibroblasts

par Ozsvari, Bela, Nuttall, John R., Sotgia, Federica, Lisanti, Michael P.
Publié dans Aging (Albany NY) (2018)

Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: Mito‐stemness and ribo‐stemness features

par Peiris‐Pagès, Maria, Ozsvári, Béla, Sotgia, Federica, Lisanti, Michael P.
Publié dans Aging (Albany NY) (2019)

Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)

par De Francesco, Ernestina Marianna, Ózsvári, Béla, Sotgia, Federica, Lisanti, Michael P.
Publié dans Front Oncol (2019)

Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)

par Ozsvari, Bela, Sotgia, Federica, Simmons, Katie, Trowbridge, Rachel, Foster, Richard, Lisanti, Michael P.
Publié dans Oncotarget (2017)

Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy

par Ozsvari, Bela, Bonuccelli, Gloria, Sanchez-Alvarez, Rosa, Foster, Richard, Sotgia, Federica, Lisanti, Michael P.
Publié dans Aging (Albany NY) (2017)

A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity

par Ózsvári, Béla, Magalhães, Luma G., Latimer, Joe, Kangasmetsa, Jussi, Sotgia, Federica, Lisanti, Michael P.
Publié dans Front Oncol (2020)

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX

par Sotgia, Federica, Ozsvari, Bela, Fiorillo, Marco, De Francesco, Ernestina Marianna, Bonuccelli, Gloria, Lisanti, Michael P.
Publié dans Cell Cycle (2018)

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity

par Bonuccelli, Gloria, Peiris-Pages, Maria, Ozsvari, Bela, Martinez-Outschoorn, Ubaldo E., Sotgia, Federica, Lisanti, Michael P.
Publié dans Oncotarget (2016)

Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability

par Kürti, Levente, Veszelka, Szilvia, Bocsik, Alexandra, Ózsvári, Béla, Puskás, László G., Kittel, Ágnes, Szabó-Révész, Piroska, Deli, Mária A.
Publié 2012

Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast

par Ozsvari, Bela, Fiorillo, Marco, Bonuccelli, Gloria, Cappello, Anna Rita, Frattaruolo, Luca, Sotgia, Federica, Trowbridge, Rachel, Foster, Richard, Lisanti, Michael P.
Publié dans Oncotarget (2017)

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease

par Lamb, Rebecca, Ozsvari, Bela, Lisanti, Camilla L., Tanowitz, Herbert B., Howell, Anthony, Martinez-Outschoorn, Ubaldo E., Sotgia, Federica, Lisanti, Michael P.
Publié dans Oncotarget (2015)

Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via “differentiation-based nano-therapy”

par Fiorillo, Marco, Verre, Andrea F., Iliut, Maria, Peiris-Pagés, Maria, Ozsvari, Bela, Gandara, Ricardo, Cappello, Anna Rita, Sotgia, Federica, Vijayaraghavan, Aravind, Lisanti, Michael P.
Publié dans Oncotarget (2015)

Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells

par Lamb, Rebecca, Ozsvari, Bela, Bonuccelli, Gloria, Smith, Duncan L., Pestell, Richard G., Martinez-Outschoorn, Ubaldo E., Clarke, Robert B., Sotgia, Federica, Lisanti, Michael P.
Publié dans Oncotarget (2015)

Neutrophils are required for both the sensitization and elicitation phase of contact hypersensitivity

par Weber, Felix C., Németh, Tamás, Csepregi, Janka Z., Dudeck, Anne, Roers, Axel, Ozsvári, Béla, Oswald, Eva, Puskás, László G., Jakob, Thilo, Mócsai, Attila, Martin, Stefan F.
Publié dans J Exp Med (2015)

Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction

par Lamb, Rebecca, Harrison, Hannah, Smith, Duncan L., Townsend, Paul A., Jackson, Thomas, Ozsvari, Bela, Martinez-Outschoorn, Ubaldo E., Pestell, Richard G., Howell, Anthony, Lisanti, Michael P., Sotgia, Federica
Publié dans Oncotarget (2015)